During the corresponding time, Mimedx Group Inc saw a revenue deteriorated by -34.27 % year on year, sequentially revenue grew by 9.79 %. While revenue at the Mimedx Group Inc 's corporate clients
Mimedx Group Inc's Comment on Sales, Marketing and Customers
The company provides products for clinicians treating patients with chronic and hard-to-heal wounds, focusing on wound care and surgical specialties. Their offerings are used when conventional treatments are ineffective and advanced therapies are required. Their placental allografts, derived from donated birth tissue sourced from a network of hospitals and clinician groups, support the healing process. The company has supplied several million allografts through direct and consignment orders. In 2024 and 2025, they incorporated additional placental allografts manufactured by a third party. They launched HELIOGEN® Fibrillar Collagen Matrix, an FDA-cleared xenograft product for complex surgical wounds, manufactured by Regenity Biosciences. The company also secured exclusive distribution agreements for RegenKit®-Wound Gel, NovaForm® Wound Matrix, G4Derm Plus®, and Hydrelix Collagen Matrix, products intended for various wound types including pressure ulcers, venous ulcers, diabetic ulcers, and surgical wounds. All products sold in the U.S. are regulated by the FDA.
The use of allografts in surgical procedures has revolutionized the field of regenerative medicine. Among the leading players in this domain is MIMEDX, an innovative biopharmaceutical company specializing in placental-based allografts. In a recent publication in Nature Scientific Reports, MIMEDX presents a comprehensive study that sheds light on the regulatory abilities of their placental-based allografts in surgical applications. This article aims to delve into the findings of this study and discuss their implications within the context of fibrosis, a common complication in surgical procedures.Understanding Placental-Based AllograftsMIMEDX utilizes Dehydrated Human Amnion/Chorion Membrane (DHACM) and Lyopre...
Mimedx Group Inc’s Comment on Sales, Marketing and Customers
The company provides products for clinicians treating patients with chronic and hard-to-heal wounds, focusing on wound care and surgical specialties. Their offerings are used when conventional treatments are ineffective and advanced therapies are required. Their placental allografts, derived from donated birth tissue sourced from a network of hospitals and clinician groups, support the healing process. The company has supplied several million allografts through direct and consignment orders. In 2024 and 2025, they incorporated additional placental allografts manufactured by a third party. They launched HELIOGEN® Fibrillar Collagen Matrix, an FDA-cleared xenograft product for complex surgical wounds, manufactured by Regenity Biosciences. The company also secured exclusive distribution agreements for RegenKit®-Wound Gel, NovaForm® Wound Matrix, G4Derm Plus®, and Hydrelix Collagen Matrix, products intended for various wound types including pressure ulcers, venous ulcers, diabetic ulcers, and surgical wounds. All products sold in the U.S. are regulated by the FDA.
Sources:
Mimedx Group Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Mimedx Group Inc’s corporate clients.
For your research, we’ve provided 9 tables on Mimedx Group Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
117.57 %